GSK plc reports

Company location
London
GSK plc has filed 6,846 SEC EDGAR filings since 12 Jan 2001

SEC filing history

Showing 51-75 of 1,000 matching filings.

Per page
25
Current page
3
6-K File 001-15170

CAMLIPIXANT PHASE III RESULTS UPDATE

Filing date
17 Jul 2026
Reporting date
17 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
16 Jul 2026
Reporting date
16 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

GSK COMPLETES ACQUISITION OF NUVALENT, INC

Filing date
15 Jul 2026
Reporting date
15 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
SC TO-T/A

SC TO-T/A

Filing date
15 Jul 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
14 Jul 2026
Reporting date
14 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
13 Jul 2026
Reporting date
13 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

POSITIVE JEMPERLI DATA IN DMMR/MSI-H RECTAL CANCER

Filing date
13 Jul 2026
Reporting date
13 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
SC TO-T/A

SC TO-T/A

Filing date
10 Jul 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

HANSOH POSITIVE PHASE III RESULTS FOR RIZ-REZ

Filing date
10 Jul 2026
Reporting date
10 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
09 Jul 2026
Reporting date
09 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTORATE CHANGE

Filing date
09 Jul 2026
Reporting date
09 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
SC TO-T/A

SC TO-T/A

Filing date
07 Jul 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TOTAL VOTING RIGHTS

Filing date
01 Jul 2026
Reporting date
01 Jul 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TRANSACTION IN OWN SHARES

Filing date
29 Jun 2026
Reporting date
29 Jun 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

HOLDING(S) IN COMPANY

Filing date
29 Jun 2026
Reporting date
29 Jun 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

HOLDING(S) IN COMPANY

Filing date
26 Jun 2026
Reporting date
26 Jun 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
SC TO-T/A

SC TO-T/A

Filing date
24 Jun 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
24 Jun 2026
Reporting date
24 Jun 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

GSK ANNOUNCES TENDER OFFER TO ACQUIRE NUVALENT

Filing date
24 Jun 2026
Reporting date
24 Jun 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

DIRECTOR/PDMR SHAREHOLDING

Filing date
23 Jun 2026
Reporting date
23 Jun 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

TRANSACTION IN OWN SHARES

Filing date
22 Jun 2026
Reporting date
22 Jun 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-15170

CUTI ORAL ANTIBIOTIC TEBIPENEM APPROVED BY US FDA

Filing date
17 Jun 2026
Reporting date
17 Jun 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .